Background and purpose: The phytocannabinoid D 9 -tetrahydrocannabivarin (D 9 -THCV) has been reported to exhibit a diverse pharmacology; here, we investigate functional effects of D 9 -THCV, extracted from Cannabis sativa, using electrophysiological techniques to define its mechanism of action in the CNS. Experimental approach: Effects of D 9 -THCV and synthetic cannabinoid agents on inhibitory neurotransmission at interneurone-Purkinje cell (IN-PC) synapses were correlated with effects on spontaneous PC output using single-cell and multi-electrode array (MEA) electrophysiological recordings respectively, in mouse cerebellar brain slices in vitro. Key results: The cannabinoid receptor agonist WIN 55,212-2 (WIN55) decreased miniature inhibitory postsynaptic current (mIPSC) frequency at IN-PC synapses. WIN55-induced inhibition was reversed by D 9 -THCV, and also by the CB 1 receptor antagonist AM251; D 9 -THCV or AM251 acted to increase mIPSC frequency beyond basal values. When applied alone, D 9 -THCV, AM251 or rimonabant increased mIPSC frequency. Pre-incubation with D 9 -THCV blocked WIN55-induced inhibition. In MEA recordings, WIN55 increased PC spike firing rate; D 9 -THCV and AM251 acted in the opposite direction to decrease spike firing. The effects of D 9 -THCV and WIN55 were attenuated by the GABA A receptor antagonist bicuculline methiodide.
Introduction
Cannabinoids represent a diverse group of compounds, including plant-derived phytocannabinoids, aminoalkylindoles (such as the prototypic WIN55) and endocannabinoids, (Di Marzo et al., 1999; Howlett et al., 2002 Howlett et al., , 2004 . Cannabinoids act on two major subtypes of G protein-coupled receptors, CB 1 and CB 2 (Alexander et al, 2007) , both of which predominantly couple to inhibitory G i/o subunits. CB 1 is strongly expressed in the CNS, particularly in the cerebellum (Tsou et al., 1998; Egertova and Elphick, 2000; Diana et al., 2002) . In contrast, CB 2 receptors are principally localized to peripheral, non-neuronal tissue (Howlett et al., 2002 ; see also Van Sickle et al., 2005; Ashton et al., 2006) . In addition to CB 1 /CB 2 -mediated effects, cannabinoids may act at further putative CB receptor subtypes, other non-CB receptors and may have other non-receptor-mediated actions (Howlett et al., 2002; Pertwee, 2007) . Plant-derived phytocannabinoids have recently attracted considerable interest as novel potential therapeutic agents (Mechoulam, 2005 , Pertwee, 2005a ; however, mechanisms of action remain poorly defined. In particular, D
9
-tetrahydrocannabivarin (D 9 -THCV), the propyl homologue of D
-tetrahydrocannabinol, has recently been reported to have a diverse pharmacology and to display tissue-dependent effects (Pertwee, 2008) . D
-THCV was originally shown to share D 9 -tetrahydrocannabinol-like properties, producing catalepsy in a mouse ring test, although at a lower potency (Gill et al., 1970 -THCV exhibits an antagonist action at CB 1 and CB 2 receptors in whole mouse brain membranes and recombinant cells, respectively (Thomas et al., 2005) . Our preliminary data also show that D
-THCV has regional effects in [ 35 S]GTPgS assays, acting as a CB 1 receptor antagonist in cerebellar and piriform cortical membranes (Dennis et al, 2007) . Plant-derived D
-THCV also acted as a functional antagonist in vitro in the isolated mouse vas deferens (Thomas et al., 2005) . Synthetic D
-THCV shared these properties and also acted as an antagonist in anti-nociceptive and hypothermia tests in vivo . In contrast, higher concentrations of D
-THCV were shown to inhibit electrically evoked responses in vas deferens reportedly by a non-CB 1 receptor-mediated mechanism (Thomas et al., 2005) and to be anti-nociceptive via an agonist effect at CB 1 receptors . Despite this recent interest, the functional effects of D
-THCV on neuronal excitability remain unknown.
In the cerebellum, activation of presynaptic CB 1 receptors at interneurone-Purkinje cell (IN-PC) synapses causes inhibition of GABA release (Takahashi and Linden, 2000; Diana et al., 2002; Kreitzer et al., 2002; Szabo et al., 2004; Yamasaki et al., 2006) , whereas CB 1 receptor activation at excitatory synapses inhibits glutamate release (Takahashi and Linden, 2000; Kreitzer and Regehr, 2001; Yamasaki et al., 2006) . Importantly, PCs represent the sole output of the cerebellar cortex. The major inhibitory drive onto PCs is provided by basket cell interneurones, which form numerous synaptic contacts in the 'pinceau' region surrounding the PC axon initial segment (Palay and Chan-Palay, 1974) . The prominent expression of CB 1 receptors within the pinceau (Tsou et al., 1998; Egertova and Elphick, 2000) provides a unique opportunity for exogenously applied cannabinoids, as well as endogenously released endocannabinoids, to modulate the overall output of the cerebellum. Activation of CB 1 receptors has been shown to play a role in cerebellar dysfunction, causing severe motor incoordination, including forms of ataxia (DeSanty and Dar, 2001; Patel and Hillard, 2001) , therefore novel modulators of CB 1 receptors have clear therapeutic potential.
Here, we perform single-cell and network-level recordings to show that D 9 -THCV, extracted from Cannnabis sativa, acts in a similar manner to standard CB 1 receptor antagonists to increase inhibitory neurotransmission at IN-PC synapses and that these actions correlate with decreases in spontaneous PC output in the cerebellum.
Methods
Tissue preparation and solutions All animal procedures complied with UK Home Office regulations (Animals (Scientific Procedures) Act 1986). Cerebellar slices were prepared according to methods described in detail previously (Harvey and Stephens, 2004) . Three-to five-week-old male TO mice (Harlan, UK) were humanely killed by cervical dislocation and decapitated. The brain was removed and transferred to chilled, carboxygenated sucrose-based artificial cerebrospinal fluid (aCSF). The cerebellum was dissected out and parasagittal cerebellar slices (300 mm thick) were cut using a Vibratome (R. & L. Slaughter, Upminster, UK). Slices were transferred into standard aCSF solution at 37 1C for 1 h and then maintained at room temperature (20-24 1C) . The standard aCSF contained NaCl 124 mM, KCl 3 mM, NaHCO 3 26 mM, NaH 2-PO 4 2.5 mM, MgSO 4 2 mM, CaCl 2 2 mM, D-glucose 10 mM, maintained at pH 7.3 by bubbling with 95% O 2 /5% CO 2 . The sucrose-based solution used for dissection and slicing was identical to standard aCSF, with the exception that NaCl was replaced by isosmotic sucrose.
Single-cell electrophysiological recording Slices were placed in a recording chamber at room temperature and perfused at 2-4 ml min -1 with standard carboxygenated aCSF. Individual neurones were visualized via a Â 60 water immersion lens with infrared differential interference contrast optics using an upright Olympus BX50WI microscope (Olympus, Tokyo, Japan). Whole-cell recordings were performed using an EPC-9 patch-clamp amplifier (HEKA Electronik, Lambrecht, Germany), controlled by Pulse software (HEKA) with a Macintosh G4 computer. Patch electrodes were made from borosilicate glass (GC150-F10, Harvard Apparatus, Kent, UK) and, when filled with an intracellular solution containing CsCl 140 mM, MgCl 2 1 mM, CaCl 2 1 mM, EGTA 10 mM, MgATP 4 mM, NaGTP 0.4 mM, HEPES 10 mM, pH 7.3, had resistances between 3 and 7 MO. Series resistance was typically 5-10 MO and was monitored and compensated by 70-90% throughout. Data were sampled at 7 kHz and filtered at one-third of the sampling frequency. Spontaneous miniature inhibitory postsynaptic currents (mIPSCs), recorded in the presence of 1 mM tetrodotoxin (TTX), were identified as rapidly activating, inward currents at a holding potential of À70 mV. Agents were applied in the presence of the non-NMDA glutamate receptor antagonist 6-nitro-7-sulphamoylbenzo(f)quinoxaline-2-3-dione (NBQX) and the GABA B receptor antagonist CGP 55845. Data were analysed using Pulsefit (HEKA), Axograph (Molecular Devices, Sunnydale, CA, USA), Igor (Wavemetrics, Lake Oswego, OR, USA), Origin (Microcal, Northampton, MA, USA) and Excel (Microsoft, Redmond, WA, USA) software. Cumulative frequency plots were constructed for mIPSC inter-event intervals (IEIs) using 5 ms bins. Data are presented as mean value ± s.e.mean, where n ¼ number of cells. Statistical significance was determined using a Student's paired t-test or a one-way ANOVA followed by Tukey's HSD test, as appropriate. Cumulative frequency plots were analysed by Kolmogorov-Smirnov tests.
MEA electrophysiological recording
Spontaneous spike activity was recorded from cerebellar slices (produced as described above) using substrate-integrated MEAs (Multi Channel Systems, Reutlingen, Germany) (Egert et al., 2002a; Stett et al., 2003) . MEAs comprised of 60 electrodes of 30 mm diameter, arranged in an 8 Â 8 array with 200 mm spacing between electrodes (Figure 5a(i) ). MEAs were cleaned before each recording using series treatments of Terg-A-Zyme (Cole-Palmer, UK), methanol and, finally, distilled water before air drying and coating. Slices were adhered to the MEA surface using an applied (B4 ml) and evaporated cellulose nitrate solution in methanol (0.24% w/v; Fisher Scientific, Loughborough, UK) ensuring maximum contact between the tissue and recording electrodes. Slice position upon the MEA was determined by observation at magnification Â 4 with a Nikon TS-51 (Nikon, Tokyo, Japan) inverted microscope and imaged via a Bresser Mikro-Okular camera (Meade, Rhede, Germany). Once placed, slices were maintained at room temperature, continuously superfused (2-4 ml min
À1
) with carboxygenated aCSF and allowed to stabilize for at least 10 min before recordings. Only data acquired from electrodes visually confirmed as proximal to the PC layer were used for analysis. Signals were amplified (1200 Â gain), band-passfiltered (10-3200 Hz) by a 60-channel amplifier (MEA60 System, Multi Channel Systems) and simultaneously sampled at 50 kHz per channel on all 60 channels. Data acquisition was to a PC using MC_Rack software (Multi Channel Systems) to monitor and record data for offline analysis.
Data analysis was performed using Neuroexplorer3 (Nex Technologies, Littleton, MA, USA) and MATLAB (Mathworks Inc., Natick, MA, USA) plus MEA Tools (Egert et al., 2002b) . Negative spike events were identified by threshold detection (minimum amplitude, À15 mV; typical noise level, p ± 5 mV; threshold determined as X3s, where s represents the s.d. of the mean of data sets without spike activity (Egert et al., 2002a) ) in MC_Rack from continuously recorded data sets of not less than 300 s duration. Spike data were exported to Neuroexplorer3 and spike rate histograms constructed using 100 ms bins. Mean spike firing rates were calculated and are presented as normalized mean±s.e.mean. Inevitable dead cell debris on the slice surface and PC depth from recording electrodes produced some variability in the apparent spontaneous firing frequency in the PC layer (typical range, 20-80 Hz; see also Egert et al., 2002a) . Consequently, druginduced changes are presented as percentage changes in firing frequency vs control firing frequency per experiment to provide normalized measures for pooled data. n numbers for MEA recordings are shown as n ¼ total number of electrodes (total number of slices). Statistical significance was determined by a non-parametric Mann-Whitney U-test. In all cases, Po0.05 was considered significant.
Materials
The following agents were used: -THCV was a kind gift of GW Pharmaceuticals (Salisbury, Wilts, UK). All drugs, except D 9 -THCV, which was supplied as a 58 mM stock solution in ethanol and stored at 4 1C, were made up as stock solutions in distilled water or dimethyl sulphoxide (AM251, CGP 55845, WIN55) and stored at À20 1C. Solvent was present at a maximum final concentration of 0.1%; solvent, applied alone at equivalent experimental concentrations, had no effect on synaptic responses in this preparation (see Bardo et al., 2002 and the Results section). Aliquots were thawed and dissolved in carboxygenated aCSF immediately before use. In all experiments, drugs were bath-applied for a minimum of 20 min to achieve steady-state effects.
Results

Effect of cannabinoids on inhibitory synaptic transmission at IN-PC synapses
Whole-cell recordings were made from PCs in acute cerebellar brain slices in the presence of 1 mM TTX (plus 5 mM NBQX and 5 mM CGP 55845) to isolate action potentialindependent GABAergic mIPSCs. Drugs were bath-applied for a minimum of 20 min to achieve steady-state effects. The CB 1 /CB 2 agonist WIN55 (1 and 5 mM) caused a clear decrease in mean mIPSC frequency (Figures 1a, b, d, e) . At 5 mM, WIN55 caused a steady-state reduction from 5.2±0.8 to 3.3 ± 0.5 Hz, equivalent to 63.2 ± 3.1% of control values (n ¼ 8; Po0.001; paired t-test); this was reflected by an increase in the mIPSC IEI by WIN55 (Figure 1d ; n ¼ 8; each replicant Po0.05; Kolmogorov-Smirnov). WIN55 had no effect on mean mIPSC amplitude (74.5 ± 10.7-71.4 ± 10.7 pA; n ¼ 8; P ¼ 0.34; paired t-test), as reflected in normalized data ( Figure 1c ). The selective CB 1 antagonist AM251 (2 mM) reversed the WIN55-induced decrease in mean mIPSC frequency (Figures 1a, b, e) ; this was to 7.1 ± 1.1 Hz, equivalent to 137.7±9.6% of control values (n ¼ 8; Po0.01; ANOVA) and reflected by a decrease in the mIPSC IEI by AM251 that exceeded control levels ( Figure 1d ; n ¼ 8; each replicant Po0.05; Kolmogorov-Smirnov). AM251 had no effect on mean mIPSC amplitude (84.2±14.8 pA; n ¼ 8; P ¼ 0.19; ANOVA), as reflected in normalized data ( Figure 1c ). In all subsequent experiments, no clear changes in mean mIPSC amplitude were seen. Reductions in mPSC frequency in the absence of effects on event amplitude are consistent with a reduction in quantal transmitter release from presynaptic sites. Although CB 2 receptor immunohistochemical labelling has recently been described in the rat cerebellum (Ashton et al., 2006) , there is, as yet, little evidence for functional CB 2 receptor activity in this region. Accordingly, the selective CB 2 agonist JWH-133 (10 mM) showed no effects on mean mIPSC frequency or amplitude (n ¼ 3; data not shown); these data were consistent with a lack of functional CB 2 receptors at IN-PC synapses. Overall, these data confirm previous studies showing that IN-PC synapses in mouse cerebellum possess functional presynaptic CB 1 receptors; moreover, the above results describing observed AM251 effects suggest that CB 1 antagonists act to increase inhibitory neurotransmission at these synapses.
Phytocannabinoids have recently attracted interest as potential therapeutic agents. Here, we examined functional effects of D 9 -THCV on neuronal excitability for the first time. D 9 -THCV reversed the WIN55-induced decrease in mean mIPSC frequency, causing increases in mean mIPSC frequency, which were beyond basal levels ( Figure 2a ). The actions of D 9 -THCV (5-58 mM), each concentration for a minimum of 20 min to achieve steady-state effects, were concentration related (Figures 2a-c) . D
9
-THCV had no effect on mean mIPSC amplitude distribution at any concentration tested. When applied alone, AM251 (2 mM: 143 ± 8.7% of control values; n ¼ 6; Po0.001; Figure 3a ), another synthetic CB 1 antagonist rimonabant (3 mM: 162 ± 22%; n ¼ 6; Po0.05; Figure 3b ) or D 9 -THCV (10 mM: 154 ± 21%; n ¼ 6; Po0.01; Figure 3c ) all caused significant steady-state increases in mean mIPSC frequency vs control levels over the time periods shown (paired t-test used for each). In all cases, no changes in mean mIPSC amplitude distribution were seen. These data indicate that D 9 -THCV acts to increase quantal GABA release at IN-PC synapses in a similar manner to selective CB 1 antagonists and, moreover, that such effects were independent of previous experimental activation of presynaptic CB 1 receptors. We next determined the effects of applying a single, maximal concentration of D . Note that WIN55 decreased mIPSC frequency, whereas AM251 caused increases beyond basal levels. Time course for effect of WIN55 (5 mM) and AM251 (2 mM) on normalized mIPSC frequency (b) and normalized mIPSC amplitude (c) (both n ¼ 8 ± s.e.mean).
(d) Cumulative frequency plots for effect of WIN55 (5 mM) and subsequent application of AM251 (2 mM) on control (CTL) mIPSC IEI (bin widths 5 ms) (all n ¼ 8±s.e.mean). (e) Bar graph showing summarized effects of WIN55 (1 mM; n ¼ 6±s.e.mean and 5 mM; n ¼ 8±s.e.mean) and of subsequent application of AM251 (2 mM, n ¼ 8±s.e.mean) in the continued presence of WIN55 (5 mM) on control (CTL, n ¼ 8±s.e.mean) normalized mIPSC frequency; *Po0.05, **Po0.01 (paired t-test or ANOVA).
In the continued presence of D 9 -THCV, the WIN55-induced inhibition was now blocked (Figures 4a and  b; 4.1±0.9 Hz ( ¼ 99±10% of D 9 -THCV values) n ¼ 5; P ¼ 0.82; ANOVA). No changes in mean mIPSC amplitude distribution were seen. These data indicate that pre-incubation with D 9 -THCV blocks WIN55 action at IN-PC synapses.
Effect of cannabinoids on PC output in cerebellar brain slices
Having demonstrated that D
9
-THCV and synthetic CB 1 antagonists act to increase inhibitory neurotransmission at IN-PC synapses, we next used MEA recordings from acute cerebellar brain slices to determine whether D 9 -THCV could also affect spontaneous PC output under conditions of basal synaptic transmission. Brain slices were cut in a sagittal plane, which maintains PC soma and dendritic tree structure and allows recording from intact PCs close to the slice surface (Egert et al., 2002a, b) . Recordings were made only from electrodes proximal to the PC layer (Figure 5a (i)) to correlate with intracellular recordings from single PCs (Figures 1-4) . Here, spikes of negative polarity, representative of single-unit or multiple single-unit excitatory events (Egert et al., 2002a) , were identified by threshold detection. Under these conditions, we recorded robust, high-frequency Figure 5a (ii)). All spontaneous activity recorded by the MEA was abolished in the presence of 1 mM TTX (n ¼ 3; data not shown), and application of the vehicle (dimethyl sulphoxide) at concentrations used for drug dilution (B0.1% v/v) revealed no observable effects upon spike firing (n ¼ 3; data not shown). Bath application of WIN55 (5 mM) caused a significant increase in normalized spontaneous mean spike firing rate (216 ± 21% of control values; n ¼ 28 (6); Po0.05; Mann-Whitney U-test; Figures 5a(ii), b(i), (ii), c, Table 1 ). Subsequent application of D
-THCV (5À40 mM), each concentration for a minimum of 20 min to achieve steady-state effects, caused clear, concentration-dependent decreases in PC spontaneous spike firing (for example, 58 mM: 49±17% of control values; n ¼ 28 (6); Po0.05; Mann-Whitney; Figures 5a(ii), b(iii), c, Table 1 ). These data demonstrate that WIN55-induced increases in PC spontaneous spike firing were opposed by D 9 -THCV. We next examined the effects of cannabinoids without pre-treatment with the CB receptor agonist WIN55. AM251 (2 mM) alone caused a significant decrease in PC spontaneous spike firing rate (68±4% of control values; n ¼ 24 (6); Po0.05; Mann-Whitney; Figures  6a-c) . Similarly, D 9 -THCV (5 mM) alone also decreased PC output (56 ± 4% of control values; n ¼ 30 (6); Po0.05; Mann-Whitney; Figure 6c ).
MEA recordings demonstrate that WIN55-induced CB 1 receptor activation caused an increase in PC spontaneous excitatory discharge, whereas D 9 -THCV and a CB 1 receptor antagonist acted to limit excitation. A clear possibility is that these data reflect modulation of inhibitory neurotransmission at IN-PC synapses (Figures 1-4) . To test this hypothesis, we examined the effects of cannabinoids in the presence of the GABA A receptor antagonist BMI. Bath application of BMI itself caused expected large increases in spontaneous spike firing frequency, at 10 mM (Po0.05; Mann-Whitney; Figure 7a (i), Table 1 ) and at 30 mM (Po0.05; Mann-Whitney; Figure 7b (i), Table 1 ). These data demonstrate that functional inhibitory input modulates spontaneous activity of PCs and hence cerebellar output. We next examined the effects of GABA A receptor blockade on cannabinoid-induced changes in PC output. In the presence of 10 mM BMI, WIN55 (5 mM) -THCV applied alone increase inhibitory neurotransmission at IN-PC synapses. Continuous data traces showing effects of (a(i)) AM251 (2 mM), (b(i)) rimonabant (3 mM) and (c(i)) D 9 -THCV (10 mM) on control (CTL) mIPSCs; in all cases, V H ¼ À70 mV. Note that each cannabinoid acted to increase mIPSC frequency. Corresponding time courses for effects of (a(ii)) AM251 (2 mM; n ¼ 6 ± s.e.mean), (b(ii)) rimonabant (3 mM; n ¼ 5 ± s.e.mean) and (c(ii)) D 9 -THCV (10 mM; n ¼ 6 ± s.e.mean). Table 1 ); however, WIN55 effects were now significantly reduced in comparison with previous control levels (216 ± 21% vs pre-BMI control compared with 155 ± 24% vs 10 mM BMI control; Po0.05; Mann-Whitney). In the presence of 10 mM BMI, D 9 -THCV still caused an overall decrease in PC firing rate, which was significant for D 9 -THCV concentrations X10 mM (all Po0.05 vs BMI control; Mann-Whitney; Figure 7a (ii); Table 1 ). However, consistent with WIN55 data, D 9 -THCV-induced inhibition of PC firing rate in the presence of 10 mM BMI was also significantly attenuated (for example, 20 mM D 9 -THCV: 15±8% vs pre-BMI control compared with 47±3% vs 10 mM BMI control; Po0.05; Mann-Whitney). In the presence of 30 mM BMI, cannabinoid effects were now abolished: no further changes in PC spontaneous firing rates were seen upon subsequent addition of WIN55 (5 mM ¼ 104 ± 3% vs 30 mM BMI control; P ¼ 0.67; Mann-Whitney; Figures 7b(i) , (ii), Table 1 Table 1 ).
The sensitivity of D
-THCV and WIN55 effects on spontaneous PC output to GABA A receptor blockade indicate that, under the experimental conditions used, cannabinoid effects are mediated by their action on inhibitory neurotransmission. More specifically, we show that D
-THCV-induced increases in GABA release can affect PC output and hence that this phytocannabinoid has the potential to modulate the output of the cerebellar cortex.
Discussion and conclusions
We have correlated patch-clamp and MEA recordings to demonstrate that D 9 -THCV acts in a manner similar to standard, selective CB 1 receptor antagonists to modulate inhibitory neurotransmission at a cellular (IN-PC synapses) and network (spontaneous PC output) level in the mouse cerebellum in vitro. We provide evidence that a CB receptor agonist reduces GABA release onto PCs leading to synaptic disinhibition, whereas D 9 -THCV acts to produce opposing effects, promoting an inhibition of spontaneous PC output.
D
-THCV modulates inhibitory neurotransmission at IN-PC synapses
We have recorded from IN-PC synapses in mouse cerebellar cortex as a suitable system to study modulation of inhibitory neurotransmission by cannabinoids. The CB receptor agonist WIN55 inhibited quantal GABA release; actions were consistent with a presynaptic effect downstream of Ca 2 þ entry, possibly via a direct action on the exocytotic release machinery, as proposed for other presynaptic GPCR agonists at IN-PC synapses (Harvey and Stephens, 2004) . Standard CB 1 receptor antagonists reversed WIN55-induced inhibition and, when applied alone, they caused an increase in GABA release over basal levels. Similar effects at IN-PC synapses have been reported in some studies (Diana et al. 2002; Kreitzer et al., 2002; Galante and Diana, 2004; Yamasaki et al., 2006) , but not others (Szabo et al., 2004) . CB 1 antagonists also increase synaptic transmission at other synapses (Melis et al., 2004; Hentges et al., 2005; Zhu and Lovinger, 2005) , suggesting that mechanisms of presynaptic regulation may be conserved between certain central synapses.
This study provides the first evidence that D
9
-THCV modulates neuronal excitability in the CNS. D 9 -THCV shared properties with synthetic CB 1 antagonists, reversing WIN55-induced inhibition of GABA release and increasing release over basal levels when applied alone; in addition, preincubation with D
-THCV blocked subsequent WIN55-induced inhibition. These data were consistent with D
-THCV acting as a functional CB 1 receptor antagonist in the CNS. CB 1 antagonist effects most likely involve removal of endocannabinergic tone, as proposed for studies at IN-PC and other central, synapses (Kreitzer et al., 2002; Galante and Diana, 2004; Melis et al., 2004; Hentges et al., 2005; Zhu and Lovinger, 2005; Neu et al., 2007) . In particular, Kreitzer et al. (2002) reported that AM251 caused an increase in interneurone firing in cerebellar brain slices, suggesting basal inhibition due to CB 1 receptor activity. Thus, although differences in cannabinoid action are reported between synapses, our data confirm that IN-PC synapses are likely to be under strong endocannabinergic inhibition. In this regard, it has recently been shown that the major endocannabinoid 2-arachidonoyl glycerol is released from PCs to (6)±s.e.mean) in the continued presence of WIN55 (5 mM) effects on PC control (n ¼ 36 (6)±s.e.mean) spontaneous excitatory spike firing rates; *Po0.05 vs control; Mann-Whitney U-test. (6)) 100 -216 ± 21* 49 ± 17* 27 ± 15* 15 ± 8* 14 ± 8* 10 mM BMI (n ¼ 38 (6) [3]
*Po0.05 vs control, wPo0.05 vs BMI control.
act retrogradely at presynaptic CB 1 receptors (Szabo et al., 2006) . Other putative mechanisms associated with receptor antagonism are less likely. The use of TTX in this study argues against mechanisms such as decreases in the rate of failures of action potential-elicited transmitter release (Neu et al., 2007) . D
-THCV and the synthetic analogue O-4394 have been reported variously to antagonize WIN55 action in isolated mouse vas deferens and D 9 -tetrahydrocannabinol-induced anti-nociception and hypothermia in vivo (Thomas et al., 2005; Pertwee et al., 2007; Pertwee, 2008 -THCV acting at CB 1 receptors (Thomas et al., 2005) ; we report broadly similar K B values and a rightward shift in WIN55 concentration-response curves induced by D
-THCV in isolated cerebellar (and piriform cortical) membranes (Dennis et al., 2007) . We have also seen that higher concentrations of D
-THCV (and AM251) can reduce [ 35 S]GTPgS binding to cerebellar membranes (Dennis et al., 2007) , which may suggest inverse agonism (MacLennan et al., 1998) . Accordingly, there is evidence that CB 1 -selective compounds AM251 and rimonabant can both act as inverse agonists and hence that CB 1 receptors may possess constitutive activity (Bouaboula et al., 1997; Pan et al., 1998; Pertwee, 2005b -THCV actions here are mediated, at least in part, by a CB 1 receptor-independent mechanism, this pathway would also have to be affected by both WIN55 and AM251. In this regard, it is also important to note that drug concentrations necessary to elicit measurable responses in brain slice preparations are difficult to relate to equilibrium-binding constants. For example, despite nanomolar affinities for CB 1 receptors, clear WIN55 effects required millimolar concentrations here and in other studies (Brown et al., 2004) . Concentration-dependence issues are exacerbated for highly lipophilic cannabinoids, which are likely to partition into lipid membranes in brain slice preparations (Howlett et al., 1989; Bloom et al., 1997) . Moreover, the end point of our assay (inhibition of vesicular GABA release) is several steps far from receptor binding/GTPgS turnover. Interestingly, higher D
-THCV doses have also been reported to have agonist actions in vivo, indicating a complex pharmacology (Pertwee, 2008) . In this study, D
-THCV had no agonist effects at IN-PC synapses; in contrast, D 9 -THCV acted in a manner opposite to the CB receptor agonist WIN55, but similar to standard CB 1 antagonists, to increase inhibitory neurotransmission.
Cannabinoids modulate spontaneous PC output in the cerebellum
The cerebellar cortex has a distinct, well-defined architecture and micro-circuitry (Ramon y Cajal, 1911; Eccles et al., 1967) , affording an ideal opportunity to study spatiotemporal network activity. We have used MEA recordings to correlate D
9
-THCV effects at IN-PC synapses with those on spontaneous PC output. Firstly, our data confirm that mouse PCs exhibit robust spontaneous activity under conditions that maintain synaptic connectivity (Egert et al., 2002a; Mapelli and D'Angelo, 2007) . This is substantiated by PC firing rates measured here being in good agreement with those recorded in vivo (Hausser and Clark, 1997; Raman and Bean, 1999) , suggesting that MEA recording in cerebellar brain slices represents an appropriate model to investigate PC output. This activity is likely to reflect spontaneous PC discharge, modulated by integrated input from spontaneously discharging inhibitory INs and recurrent PC collaterals (Palay and Chan-Palay, 1974; Hausser and Clark, 1997; Mann-Metzer and Yarom, 1999) . We extend previous studies to provide the first examination of drug effects on spontaneous PC activity using MEA methods. WIN55 caused clear increases in excitatory spike firing rate consistent with a decrease in GABA release at IN-PC synapses leading to synaptic disinhibition. Conversely, D
-THCV reversed WIN55 effects and when applied alone it decreased -THCV causing an increased GABAergic inhibition, manifest as an overall decrease in spontaneous PC activity. Again, D
-THCV effects on PC output were similar to those seen for the CB 1 antagonist AM251. Direct CB 1 receptor-mediated postsynaptic effects (such as apparent reductions in firing rate due to spike amplitude falling below the detection threshold) are unlikely as PCs do not express significant CB 1 receptor numbers (Matsuda et al., 1993; Egertova and Elphick, 2000; Freund et al., 2003) . Activation of presynaptic CB 1 receptors leads to reduction in transmitter release; the overall increase in excitability at a network level is consistent with cannabinoid-mediated modulation of inhibitory neurotransmission at IN-PC synapses being reflected in spontaneous PC output. This hypothesis is supported by the concentration-dependent abolition of WIN55 and D
-THCV effects by the GABA A receptor antagonist BMI, which blocks phasic and tonic GABA currents at mouse IN-PC synapses (Harvey et al., 2006) . Interestingly, although cannabinoid actions were reduced by 10 mM BMI, it was necessary to use 30 mM BMI to ensure complete block; however, this concentration is well within ranges commonly -THCV increases GABA release at inhibitory terminals (including IN-PC synapses) to cause a decrease in spontaneous PC output; thus, we demonstrate that D
-THCV has the potential to modulate network activity within the cerebellar cortex.
Functional relevance
We show that D
9
-THCV (and the CB 1 receptor antagonist AM251) acts to increase inhibitory neurotransmission to cause any overall decrease in PC output under the conditions used. In contrast, the CB agonist WIN55 decreased GABA release and caused synaptic disinhibition of PCs. PCs project inhibitory innervation to deep cerebellar nuclei (DCN) to control their intrinsic firing rate (Gauck and Jaeger, 2000) ; in turn, DCN supply areas such as the vestibular nucleus and motor cortex to coordinate movement, balance and posture. Abnormally high spiking activity can damage neurones and lead to degenerative disease. Moreover, excessive PC activation has been proposed to increase inhibition of DCN and lead to cerebellar dysfunction (Patel and Hillard, 2001 ). Importantly, CB 1 receptor agonists have been shown to promote cerebellar dysfunction in behavioural tests, in particular causing severe motor incoordination (DeSanty and Dar, 2001; Patel and Hillard, 2001) . Therefore, decreases in GABA release at IN-PC synapses due to excessive endocannabinoid release would be expected to result in PC disinhibition and a corresponding increased inhibition of DCN, which may then precipitate cerebellar dysfunction. Agents that increase inhibitory neurotransmission, such as D
-THCV, will cause opposing effects, reducing PC output and ultimately facilitating the control of posture and movement by DCN. These studies suggest that D 9 -THCV, alongside standard CB 1 receptor antagonists, has therapeutic potential to combat diseases involving cerebellar dysfunction and hyperexcitability. For example, our preliminary studies suggest that D 9 -THCV may be anti-convulsant in a developmental model of epilepsy (Weston et al., 2006; see Pertwee, 2008) . Our data support recent proposals that phytocannabinoids may represent important, but neglected, therapeutic agents (Mechoulam, 2005) . It will be of interest in future studies to investigate how different phytocannabinoids may similarly modulate disease states in the CNS.
